Newsfeeds - Spark Newswire

2 minute read

Legal
News

Aclaris Therapeutics Announces Proposed Settlement And Settlement Hearing Of Stockholder Derivative Action

Today, 4:01 AM

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that a settlement hearing (the

ACRS

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

Today, 4:01 AM

Gainers

ACRS

16 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For June 15, 2021

By Benzinga Insights

Today, 4:01 AM

ACRS

1 minute read

Piper Sandler Initiates Coverage On Aclaris Therapeutics with Overweight Rating, Announces Price Target of $30

By Benzinga Newsdesk

Today, 4:01 AM

Piper Sandler analyst Christopher Raymond initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight rating and announces Price Target of $30.

ACRS